for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novartis AG

NOVN.S

Latest Trade

77.39CHF

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

65.09

 - 

96.38

As of on the Virt-X ∙ Minimum 15 minute delay

Pricing

Previous Close
77.39
Open
--
Volume
--
3M AVG Volume
127.42
Today's High
--
Today's Low
--
52 Week High
96.38
52 Week Low
65.09
Shares Out (MIL)
2,288.98
Market Cap (MIL)
187,008.70
Forward P/E
14.45
Dividend (Yield %)
3.91

Next Event

Novartis AG ESG Investor Event

Latest Developments

More

Novartis’ Sandoz Announces €150 Mln Investment In Austrian Antibiotics Plant

EMA Says CHMP Adopts Positive Opinion For Calquence For Treatment Of Chronic Lymphocytic Leukaemia

Novartis Says Phase 3 Study Of Jakavi In Chronic Graft-Versus-Host Disease Met Primary Endpoints

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

Industry

Major Drugs

Contact Info

Lichtstrasse 35

4056

Switzerland

+41.61.3241111

https://www.novartis.com/

Executive Leadership

Joerg Reinhardt

Independent Non-Executive Chairman of the Board

Alex Krauer

Honorary Chairman of the Board

Daniel L. Vasella

Honorary Chairman of the Board

Vasant Narasimhan

Chief Executive Officer, Member of the Executive Committee

Enrico Vanni

Independent Non-Executive Vice Chairman of the Board

Key Stats

2.15 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

49.1K

2018

51.9K

2019

47.4K

2020(E)

49.8K
EPS (USD)

2017

4.860

2018

5.150

2019

5.400

2020(E)

5.724
Price To Earnings (TTM)
26.48
Price To Sales (TTM)
4.14
Price To Book (MRQ)
3.53
Price To Cash Flow (TTM)
16.13
Total Debt To Equity (MRQ)
64.64
LT Debt To Equity (MRQ)
47.67
Return on Investment (TTM)
7.99
Return on Equity (TTM)
6.01

Latest News

Latest News

Novartis's Kymriah meets endpoint in follicular lymphoma trial

Novartis CAR-T cell therapy Kymriah met its primary endpoint at an interim analysis of a phase-II trial in patients with relapsed or refractory follicular lymphoma, the Swiss drugmaker said on Tuesday.

Novartis gets European approval for psoriasis drug Cosentyx

Novartis has received European Union approval for its Cosentyx drug to be a standard treatment for psoriasis in children, the company said on Monday.

Novartis sickle cell drug Adakveo put on path to EU approval

Novartis's sickle cell disease treatment Adakveo appears set for European approval after a key committee on Friday gave its backing to the drug that booked $36 million in first-half U.S. sales.

Biogen to study Spinraza in combination with $2 mln Novartis drug

One of medicine's costliest treatment areas could become even more pricey as Biogen seeks to layer its $750,000 spinal muscular atrophy drug on top of $2.1 million-per-patient Novartis gene therapy Zolgensma.

Novartis trims sales outlook after hit from COVID disruptions

Novartis CEO Vas Narasimhan cut the Swiss drugmaker's 2020 sales forecast on Tuesday after COVID-19 disruptions that kept patients from visiting their doctor or hospital hit the company's second-quarter revenue.

Novartis says Zolgensma patients kept gains as Biogen eyes follow-up trial

Novartis Chief Executive Vas Narasimhan said spinal muscular atrophy patients who got the Swiss drugmaker's Zolgensma maintained improvements, a response to Biogen's plan to test its drug Spinraza after Zolgensma treatment.

Novartis to provide 'no profit' COVID-19 drugs to low income countries

Novartis's Sandoz division will not profit from 15 generic drugs it is making available to developing countries to treat symptoms of COVID-19 for the pandemic's duration, the Swiss drugmaker said on Thursday.

Novartis to provide 'no profit' COVID-19 drugs to low-income countries

Novartis's Sandoz division will not make a profit on 15 generic drugs it is making available to developing countries to treat symptoms of COVID-19, the Swiss drugmaker said on Thursday.

BRIEF-Novartis Says Phase 3 Iridium Data In Lancet Respiratory Medicine Show Benefit Of Enerzair Breezhaler

* NOVARTIS PHASE III IRIDIUM DATA IN LANCET RESPIRATORY MEDICINE SHOW BENEFIT OF ENERZAIR® BREEZHALER® (QVM149), THE FIRST-IN-CLASS INHALED LABA/LAMA/ICS COMBINATION IN UNCONTROLLED ASTHMA

BRIEF-Sosei Group Corp - Partner Novartis Gets European Commission Approval For Enerzair Breezhaler Asthma Treatment

* PARTNER NOVARTIS GETS EUROPEAN COMMISSION APPROVAL FOR ENERZAIR BREEZHALER ASTHMA TREATMENT

BRIEF-Novartis Gets European Commission Approval For Enerzair Breezhaler Asthma Treatment

* NOVARTIS RECEIVES EC APPROVAL FOR ENERZAIR® BREEZHALER®, INCLUDING FIRST DIGITAL COMPANION (SENSOR AND APP) THAT CAN BE PRESCRIBED ALONGSIDE A TREATMENT FOR UNCONTROLLED ASTHMA IN EU Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)

Novartis pays $729 million to settle U.S. kickback charges

Novartis AG agreed to pay more than $729 million to settle U.S. government charges it paid illegal kickbacks to doctors and patients to boost drug sales, the U.S. Department of Justice said on Wednesday.

BRIEF-Novartis Resolves Legacy Litigation Matters, Finalizing Settlement Of Speaker Program Litigation With U.S. Govt

* NOVARTIS RESOLVES LEGACY LITIGATION MATTERS, FINALIZING SETTLEMENT OF SPEAKER PROGRAM LITIGATION WITH GOVERNMENT IN THE US AND POSITIONING COMPANY FOR THE FUTURE BY FULLY SCALING ITS NEXT-GENERATION DIGITAL ENGAGEMENT TECHNOLOGIES

BRIEF-U.S. DOJ Says Novartis Agrees To Pay Over $51 Mln To Resolve Allegations That It Paid Kickbacks Through Co-Pay Foundations

* U.S. DOJ SAYS NOVARTIS AGREES TO PAY OVER $51 MILLION TO RESOLVE ALLEGATIONS THAT IT PAID KICKBACKS THROUGH CO-PAY FOUNDATIONS Source text : https://bit.ly/2ApnnPS Further company coverage:

Amgen patents on top-selling arthritis drug Enbrel upheld, shares rise

A U.S. appeals court on Wednesday upheld two patents for Amgen Inc's multibillion-dollar rheumatoid arthritis drug Enbrel in a defeat for Novartis AG, which has been trying to sell its own version.

Amgen defeats Novartis appeal over arthritis drug Enbrel's patents

A federal appeals court on Wednesday upheld two patents for Amgen Inc's multibillion-dollar rheumatoid arthritis drug Enbrel, rejecting Novartis AG's effort to void the patents.

BRIEF-Novartis Receives Japanese Health Ministry's Approval For Five Products

* NOVARTIS RECEIVES SIMULTANEOUS APPROVAL FOR FIVE NEW PRODUCTS FROM JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFARE, OFFERING JAPANESE PATIENTS A BROAD RANGE OF NOVEL TREATMENT OPTIONS

Japan's Takeda expects $200 million operating loss related to Novartis' Xiidra withdrawal

Takeda Pharmaceutical Co Ltd <4502.T> said on Monday it anticipates an operating loss of about $200 million related to Novartis AG's decision to withdraw a marketing application for the dry-eye drug Xiidra.

Novartis pulls dry eye drug Xiidra's bid for approval in Europe

Swiss drugmaker Novartis has withdrawn an application for European approval of its Xiidra dry eye medicine after regulators concluded its effectiveness had not been demonstrated and that its benefits did not outweigh risks.

BRIEF-Novartis: Cosentyx Gets Positive CHMP Opinion For Pediatric Psoriasis

* NOVARTIS COSENTYX® GAINS POSITIVE CHMP OPINION FOR PEDIATRIC PSORIASIS, REINFORCING ESTABLISHED EFFICACY AND SAFETY PROFILE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up